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ABSTRACT 24 
 25 
Study question 26 
Are the published pre-treatment and post-treatment McLernon models, predicting cumulative live birth 27 
rates (LBR) over multiple complete IVF cycles, valid in a different context? 28 
 29 
Summary answer  30 
With minor recalibration of the pre-treatment model, both McLernon models accurately predict 31 
cumulative LBR in a different geographical context and a more recent time period.  32 
 33 
What is known already  34 
Previous IVF prediction models have estimated the chance of a live birth after a single fresh embryo 35 
transfer, thereby excluding the important contribution of embryo cryopreservation and subsequent IVF 36 
cycles to cumulative LBR. In contrast, the recently developed McLernon models predict the cumulative 37 
chance of a live birth over multiple complete IVF cycles at two certain time points: a) before initiating 38 
treatment using baseline characteristics (pre-treatment model) and b) after the first IVF cycle adding 39 
treatment related information to update predictions (post-treatment model). Before implementation of 40 
these models in clinical practice, their predictive performance needs to be validated in an independent 41 
cohort.  42 
 43 
Study design, size, duration  44 
External validation study in an independent prospective cohort of 1515 Dutch women who participated in 45 
the OPTIMIST study (NTR2657) and underwent their first IVF treatment between 2011 and 2014. 46 
Participants underwent a total of 2881 complete treatment cycles, with a complete cycle defined as all 47 
fresh and frozen thawed embryo transfers resulting from one episode of ovarian stimulation. The follow 48 
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up duration was 18 months after inclusion, and the primary outcome was ongoing pregnancy leading to 49 
live birth. 50 
 51 
Participants/materials, setting, methods 52 
Model performance was externally validated up to three complete treatment cycles, using the linear 53 
predictor as described by McLernon et al. to calculate the probability of live birth. Discrimination was 54 
expressed by the c-statistic and calibration was depicted graphically in a calibration plot. In contrast to the 55 
original model development cohort, anti-Müllerian hormone (AMH), antral follicle count (AFC) and body 56 
weight were available in the OPTIMIST cohort, and evaluated as potential additional predictors for model 57 
improvement.  58 
 59 
Main results and the role of chance  60 
Applying the McLernon models to the OPTIMIST cohort, the c-statistic of the pre-treatment model was 61 
0.62 (95% confidence interval (CI) 0.59-0.64) and of the post-treatment model 0.71 (95% CI 0.69-0.74). 62 
The calibration plot of the pre-treatment model indicated slight overestimation of the cumulative LBR. To 63 
improve calibration, the pre-treatment model was recalibrated by subtracting 0.35 from the intercept. The 64 
post-treatment model calibration plot revealed accurate cumulative LBR predictions. After addition of 65 
AMH, AFC and body weight to the McLernon models, the c-statistic of the updated pre-treatment model 66 
improved slightly to 0.66 (95% CI 0.64-0.68), and of the updated post-treatment model remained at the 67 
previous level of 0.71 (95% CI 0.69-0.73). 68 
Using the recalibrated pre-treatment model, a woman aged 30 years with two years of primary infertility 69 
who starts ICSI treatment for male factor infertility has a chance of 40% of a live birth from the first 70 
complete cycle, increasing to 72% over three complete cycles. If this woman weighs 70 kilograms, has an 71 
AMH of 1.5 ng/mL and an AFC of 10 measured at the beginning of her treatment, the updated pre-72 
treatment model revises the estimated chance of a live birth to 30% in the first complete cycle and 59% 73 
over three complete cycles. If this woman then has 5 retrieved oocytes, no embryos cryopreserved and a 74 
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single fresh cleavage stage embryo transfer in her first ICSI cycle, the post-treatment model estimates the 75 
chances of a live birth at 28% and 58%, respectively. 76 
 77 
Limitations, reasons for caution 78 
Two randomised controlled trials (RCT) evaluating the effectiveness of gonadotropin dose 79 
individualisation on basis of the AFC were nested within the OPTIMIST study. The strict dosing 80 
regimens, the RCT in- and exclusion criteria and the limited follow up time of 18 months might have 81 
influenced model performance in this independent cohort. Also, consistent with the original development 82 
study, external validation was performed using the optimistic assumption that the cumulative LBR in 83 
couples that discontinue treatment without a live birth would have been equal to that of couples who 84 
continue treatment.  85 
 86 
Wider implications of the findings  87 
After national recalibration to account for geographical differences in IVF/ICSI treatment, the McLernon 88 
prediction models can be introduced as new counselling tools in clinical practice to inform patients and to 89 
complement clinical reasoning. These models are the first to offer an objective and personalised estimate 90 
of the cumulative probability of live birth over multiple complete IVF cycles.  91 
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Introduction  108 
Infertility is defined as the failure to conceive within 12 months of regular unprotected intercourse, and  109 
affects approximately one in six couples (Oakley et al., 2008; Zegers-Hochschild et al., 2017). The 110 
majority of infertile couples seek fertility care, and many of those with prolonged unresolved infertility 111 
will be treated with ART regardless of cause (Boivin et al., 2007; Datta et al., 2016). IVF and ICSI are 112 
both widely used techniques for couples with infertility. Globally more than 1.6 million annual cycles of 113 
IVF/ICSI are performed and while success rates have increased over time (Dyer et al., 2016; McLernon et 114 
al., 2016), this treatment is still not effective for all infertile couples, with live birth rates (LBR) at around 115 
25-30% per treatment cycle (Malizia et al., 2009; McLernon et al., 2016; De Neubourg et al., 2016). 116 
Since IVF/ICSI is expensive and carries several risks, the probability of a live born child should be 117 
weighed against the risks and costs of this treatment. 118 
Several prognostic models have been developed to objectively estimate the probability of a live birth after 119 
IVF/ICSI treatment (Leushuis et al., 2009; van Loendersloot et al., 2014). It is known that prediction 120 
models often perform optimistically in their development sample, even after correction by internal 121 
validation. This is caused by overfitting, which occurs when the model corresponds too closely to the 122 
development data due to the inclusion of too many predictors (Moons, Kengne, Woodward, et al., 2012). 123 
External validation in an independent cohort of women is thus essential to examine the performance and 124 
generalisability of the prediction model (Altman et al., 2009; Harrell et al., 1996). Unfortunately, most of 125 
the currently available models that predict the chance of a live birth after IVF/ICSI treatment have never 126 
been externally validated (Leushuis et al., 2009; van Loendersloot et al., 2014). Also, the majority of 127 
these models predict the probability of a live birth after a single fresh embryo transfer, excluding the 128 
important contribution of embryo cryopreservation and subsequent treatment cycles to LBR. This limits 129 
their potential as counselling tools for couples and clinicians, especially considering the increased use and 130 
improved techniques of embryo cryopreservation and frozen thawed embryo transfer cycles in recent 131 
years (Wong et al., 2014). 132 
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Three of the largest model development studies for prediction of live birth after IVF and/or ICSI 133 
treatment used data from the Human Fertilisation and Embryology Authority (HFEA) database in the UK 134 
(McLernon et al., 2016; Nelson and Lawlor, 2011; Templeton et al., 1996). Treatment and outcome data 135 
from all licenced fertility clinics within the UK have been recorded in this database since 1992. The two  136 
models developed by Templeton et al. and Nelson et al. were both externally validated, and their 137 
predictive performance was compared to one another in several studies (Arvis et al., 2012; van 138 
Loendersloot et al., 2011; Smeenk et al., 2000; Smith et al., 2015; te Velde et al., 2014). Although these 139 
models have been recommended in previous studies and used internationally to predict live birth after 140 
IVF and ICSI (Leushuis et al., 2009; Smith et al., 2015; te Velde et al., 2014), neither model predicts 141 
cumulative LBR over multiple IVF/ICSI treatment cycles including frozen thawed embryo transfer 142 
cycles.  143 
Recently, a new model was developed by McLernon et al. using the HFEA database (McLernon et al., 144 
2016). This model is the first to provide an individualised estimate of the cumulative chance of a live 145 
birth over multiple complete cycles of IVF/ICSI, with a complete cycle defined as all fresh and frozen 146 
thawed embryo transfers resulting from one episode of ovarian stimulation. For model development, data 147 
from 113 873 women and 184 269 complete cycles between 1999 and 2009 were used. Internal validation 148 
of the model showed promising results, however evaluation of the predictive performance of the model in 149 
a different geographical context using more contemporary data has yet to be performed. Additionally, a 150 
number of potential key predictors, such as measures for ovarian reserve and female body weight, were 151 
unavailable in the HFEA database and could not be included in the original model (McLernon et al., 152 
2016). 153 
The main objective of the current study was therefore to perform geographical and temporal validation of 154 
the new HFEA model by using recent data from a different country. We also wanted to determine whether 155 
inclusion of additional parameters, such as female body weight and ovarian reserve test results i.e. antral 156 
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follicle count (AFC) and anti-Müllerian hormone (AMH), could improve the predictive performance of 157 
the model.  158 
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Materials and methods  159 
Data sources  160 
External validation was performed on data from the OPTIMIST study (van Tilborg, Oudshoorn, et al., 161 
2017). This multicentre prospective cohort study included 1515 women from 25 infertility centres in the 162 
Netherlands between May 2011 and May 2014. Participants were younger than 44 years of age, had 163 
regular menstrual cycles and no significant uterine or ovarian abnormalities on transvaginal ultrasound. 164 
Women with polycystic ovarian syndrome, metabolic or endocrine abnormalities or undergoing oocyte 165 
donation were excluded. All participants were included before their first IVF/ICSI cycle, or the first cycle 166 
after a previous live birth. The primary outcome was ongoing pregnancy, achieved within 18 months of 167 
follow up, and resulting in live birth. Ethical approval for the OPTIMIST study was obtained from the 168 
Institutional Review Board of the University Medical Centre Utrecht (MEC 10-273), and all participants 169 
provided written informed consent. A more detailed description of study procedures and results were 170 
reported previously (Oudshoorn et al., 2017; van Tilborg et al., 2012; van Tilborg, Oudshoorn, et al., 171 
2017; van Tilborg, Torrance, et al., 2017).  172 
McLernon model 173 
The McLernon model consists of two clinical prediction models to estimate the individualised cumulative 174 
chance of a live birth over a maximum of six complete treatment cycles. Before initiating treatment, the 175 
pre-treatment model predicts the probability of a live birth from both fresh and frozen thawed embryo 176 
transfers based on couple characteristics and the use of IVF or ICSI. Included predictors are: female age 177 
(years), duration of infertility (years), previous pregnancy, causes of infertility (tubal factor, anovulation, 178 
male factor, unexplained infertility), type of treatment (IVF or ICSI) and treatment year (see 179 
Supplementary Text 1).  180 
After the first fresh treatment cycle, treatment specific characteristics from this cycle are added in the 181 
post-treatment model to update the predicted probability. Added predictors are: number of oocytes, 182 
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cryopreservation of embryos, and the number and stage of embryos at the first fresh embryo transfer 183 
(single, double or triple embryo transfer; blastocyst or cleavage stage). All causes of infertility are 184 
excluded as predictors in the post-treatment model, except for tubal factor (see Supplementary Text 2). 185 
For women with zero oocytes collected in the first cycle, a separate post-treatment model is available. 186 
To predict the probability of a live birth in the ith cycle, assuming no live birth occurred in the previous 187 
cycle(s), complete cycle number is included in both models as a discrete time variable. A complete cycle 188 
includes all fresh and frozen thawed embryo transfers resulting from one episode of ovarian stimulation. 189 
With the predicted probability of a live birth per subsequent complete cycle, the cumulative probability of 190 
a live birth can be calculated up to six complete cycles (see Supplementary Text 1 and 2).  191 
Statistical analysis 192 
Nine predictor variables had missing values (Table I). The proportion of missing values was low (< 193 
2.5%), except for AMH (11.2%). During the OPTIMIST study, blood sampling was performed on the day 194 
of randomisation. Logistic issues prevented blood sampling in some cases, thus compromising the ability 195 
to undertake post-hoc measurements of AMH in the total population. As the reasons for missing values 196 
were considered to be unrelated to the AMH value itself or the measurement, these were defined as 197 
missing (completely) at random.  198 
Multiple imputation was applied for predictors with missing values in the OPTIMIST database (Sterne et 199 
al., 2009). In this process 10 imputed datasets were created using a multivariate imputation by chained 200 
equations (MICE) algorithm (van Buuren and Groothuis-Oudshoorn, 2011). Predicted probabilities for a 201 
live birth were calculated on each imputed dataset, using the predictors and parameter-estimates of both 202 
the pre-treatment model as well as the post-treatment model as described by McLernon et al 2016 203 
(McLernon et al., 2016). In accordance with the original models, the variables female age, treatment year 204 
and number of oocytes were treated with restricted cubic splines in the validation process. The separate 205 
post-treatment model for women with zero oocytes collected in the first treatment cycle was not validated 206 
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in this study, as the number of women for this analysis was too low in the OPTIMIST database. 207 
Cumulative probabilities were calculated up to three complete IVF/ICSI cycles, as most couples in the 208 
Netherlands only have three treatment cycles due to the current reimbursement policy. Also, the 209 
OPTIMIST follow up period was 18 months, reducing the number of women with more than three 210 
treatment cycles. The validation process was performed ten times on each of the imputed datasets and 211 
separate results were pooled using Rubin’s rules (Rubin, 2004). 212 
The predictive performance of the McLernon models was evaluated in terms of discrimination and 213 
calibration. Discrimination quantifies the ability of a model to correctly differentiate between subjects 214 
with an event and subjects without an event (Moons, Kengne, Woodward, et al., 2012). In the context of 215 
fertility treatment, it is the ability of the models to distinguish between women with a live birth and 216 
women without a live birth after IVF/ICSI treatment. It is expressed by the c-statistic or the area under the 217 
receiver operating curve (AUROC), which ranges between 0.5 and 1. A c-statistic of 1 indicates perfect 218 
discrimination, whereas a c-statistic of 0.5 represents a model with no discrimination at all. In this study, 219 
the c-statistic (and 95% CI) was calculated using the method suggested by Harrell et al. (Harrell et al., 220 
1996). 221 
Calibration describes the degree of agreement between predicted probabilities and observed outcomes 222 
(Moons, Kengne, Woodward, et al., 2012), in this context the predicted probability of a live birth and the 223 
observed LBR. Calibration can be assessed graphically by forming subgroups of patients determined by 224 
ranges of predicted probabilities, and then plotting the observed proportion of events against the mean 225 
predicted probability within these subgroups. When perfect calibration is present, the plot shows a 226 
diagonal line with a slope of one and an intercept of zero. In the current study, five equal subgroups of 227 
patients were formed. This was based on the sample size of the OPTIMIST cohort and the related 228 
precision of the point estimates in the calibration plot. Within these subgroups, the Kaplan Meier 229 
estimates of the observed cumulative LBR over three complete treatment cycles were plotted against the 230 
mean predicted probability of cumulative live birth. A smoothed line was then added in this plot using the 231
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proportional hazard regression approach described by Harrell et al (Harrell et al., 1996). In addition to 232 
this, a systematic difference in the predicted and observed LBR was assessed by using calibration-in-the-233 
large (Steyerberg, 2009), and the intercept of the prediction models was adjusted in case a systematic 234 
over- or underestimation was present.   235 
Updating the models 236 
Following the external validation of the models, the additional value of updating the McLernon models 237 
with pre-specified new biomarkers was evaluated. AMH (ng/mL), AFC (2-10 mm) and body weight (kg) 238 
were added to the pre-treatment and post-treatment model in a multivariable logistic regression analysis, 239 
in which the linear predictor of the McLernon model was entered as a fixed variable. The final model was 240 
established using a manual backward selection process. Predictors were eliminated from the model 241 
according to the Akaike Information Criterion (AIC) (Akaike, 1974).  242 
The predictive performance of the new updated models was evaluated by calculating the c-statistic (and 243 
95% CI). To assess for overfitting, internal validation was performed by bootstrapping (Steyerberg, 244 
2009). Two hundred bootstrap samples, all of which were of the same size as the original validation 245 
sample, were created by random sampling with replacement (Harrell, 2001; Steyerberg, 2009). In each 246 
bootstrap sample, a new model was fitted with the same predictors as the updated models. The c-statistic 247 
was calculated for each of the 200 sample derived models, in both the bootstrap sample as well as the 248 
original validation cohort. The difference between these two c-statistics was calculated for each of the 200 249 
sample derived models, and averaged to give the optimism estimate. This was subtracted from the 250 
original c-statistic to obtain the optimism corrected c-statistic for the updated models.  251 
All statistical analyses were performed using R for Windows (version 3.3.2; R Foundation for Statistical 252 
Computing, Vienna, Austria).  253 
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Results  254 
Of the 1515 women included in the OPTIMIST study, four were excluded in the current study as they 255 
never started IVF/ICSI treatment. A total of 2881 IVF/ICSI cycles were performed over a period of 18 256 
months of follow up. Table I shows the patient and first cycle treatment characteristics of the OPTIMIST 257 
cohort (validation sample) and the HFEA cohort (development sample). Women included in the 258 
validation sample were about the same age as women in the development sample, but had a shorter 259 
average duration of infertility. The causes of infertility showed a similar distribution across both samples, 260 
with the exception of anovulation which rendered women ineligible for the OPTIMIST study. The 261 
treatment characteristics showed that embryo cryopreservation was more frequently performed after the 262 
first IVF/ICSI cycle in the validation sample and that these women most often had a cleavage stage single 263 
embryo transfer in the first fresh cycle, whereas women in the development sample most often had a 264 
cleavage stage double embryo transfer. No formal assessment was performed for the differences and 265 
similarities between the cohorts, as a description rather than a p-value is considered to be useful for 266 
interpretation of the models’ performance in this external validation study.  267 
The flowchart in Figure 1 shows the number of women in the OPTIMIST and HFEA cohorts who started 268 
a treatment cycle, had a live birth or discontinued treatment without having a live birth. The LBR per 269 
cycle was similar in both cohorts for the first, second and fourth treatment cycle. In the third cycle the 270 
LBR was slightly higher in the OPTIMIST cohort compared to the HFEA cohort. As few women in the 271 
OPTIMIST cohort received a fifth or sixth cycle, LBR in these cycles could not be compared. The 272 
proportion of women without a live birth that continued treatment was higher after the first and second 273 
cycle in the OPTIMIST cohort as compared to the HFEA cohort. After the third cycle, the proportion 274 
continuing treatment in the OPTIMIST cohort decreased, while it remained constant in the HFEA cohort. 275 
At the end of follow up, 52% of the women in the OPTIMIST study had a treatment related live birth. The 276 
overall LBR of the HFEA cohort was 43% over six complete IVF/ICSI cycles.  277 
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As mentioned previously, external validation of the McLernon models was performed up to three 278 
complete treatment cycles, and therefore the fourth, fifth and sixth complete treatment cycle in the 279 
OPTIMIST dataset (n=102 complete treatment cycles, n= 15 live births) were excluded from further 280 
analysis. Also, for the post-treatment model validation, women with zero oocytes collected in the first 281 
treatment cycle were excluded (n= 226 women, n = 526 complete treatment cycles, n= 82 live births) as a 282 
separate model was developed for this group of women by McLernon et al (McLernon et al., 2016). Due 283 
to the small numbers, this separate model could not be validated in this study. 284 
Discrimination and calibration 285 
In the validation sample, the pooled c-statistic for the pre-treatment model was 0.62 (95% CI 0.59-0.64) 286 
and for the post-treatment model 0.71 (95% CI 0.69-0.74). Figure 2a and 3 show the calibration plots for 287 
both original models, depicting the correlation between the observed and predicted cumulative LBR. The 288 
pre-treatment calibration plot had an intercept of -0.23 (95% CI -0.36- -0.10) and a slope of 0.98 (95% CI 289 
0.69-1.27), and the post-treatment calibration plot had an intercept of -0.01 (95% CI -0.12-0.11) and a 290 
slope of 0.97 (95% CI 0.77-1.19).  291 
The pre-treatment model systematically overestimated the cumulative LBR over three complete cycles for 292 
women in the validation sample. This is shown by a calibration curve with most of the confidence 293 
intervals under the reference line (Figure 2a), indicating significantly higher predicted probabilities than 294 
observed LBR. The calibration-in-the-large analysis confirmed this systematic overestimation with an 295 
intercept of  -0.35. To improve calibration, the pre-treatment model was thus adjusted by subtracting 0.35 296 
from the intercept of the original linear predictor, which decreased the predicted odds of a live birth by a 297 
factor of 1.42 (see Supplementary Text 3). The calibration plot of the recalibrated pre-treatment model 298 
showed improved accuracy of the predictions, with all confidence intervals overlapping the reference line 299 
(Figure 2b). In contrast to the pre-treatment model, the post-treatment model correctly estimated the 300 
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cumulative LBR in the validation sample, as is shown by a calibration plot with confidence intervals 301 
overlapping the reference line indicating no significant over- or underestimation (Figure 3).  302 
Updating of the models 303 
Addition of the biomarkers AMH, AFC and body weight to the pre-treatment and post-treatment model in 304 
a multivariable regression analysis resulted in two new updated models. The updated pre-treatment model 305 
included all three biomarkers as additional predictors for live birth. Since the relationship between both 306 
AMH and AFC with the probability of live birth was non-linear, these predictors were included using 307 
restricted cubic splines (see Supplementary Figure 1). The updated post-treatment model included only 308 
AFC and AMH as additional predictors for live birth, of which AFC was modelled by using restricted 309 
cubic splines (see Supplementary Figure 2). After internal validation of the updated models by 310 
bootstrapping, the updated pre-treatment model had a corrected c-statistic of 0.66 (95% CI 0.64-0.68) and 311 
the updated post-treatment model had a corrected c-statistic of 0.71 (95% CI 0.69-0.73). The addition of 312 
AFC, AMH and body weight thus resulted in a slight improvement of the discriminatory capacity of the 313 
pre-treatment model, while addition of AFC and AMH had no beneficial effect on the discriminative 314 
performance of the post-treatment model.  315 
Examples of model predictions 316 
Figures 4, 5 and 6 show examples of model predictions as illustration for clinical application. Figure 4 317 
presents predictions of the recalibrated pre-treatment model for couples with primary infertility caused 318 
by a male factor. Cumulative probabilities of live birth are calculated up to three complete ICSI cycles, 319 
and are differentiated by female age (30 or 40 years) and duration of infertility (2 years or 5 years). As is 320 
shown in figure 4, age is the most important predictor in the pre-treatment model. A 30-year-old woman 321 
with 2 years of infertility has a predicted probability of a live birth of 0.40 in the first ICSI cycle, 322 
increasing to 0.72 over three complete cycles. For a 40-year-old woman with 2 years of infertility, these 323 
probabilities are 0.15 and 0.32 respectively. 324 
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Figure 5 shows predictions of the updated pre-treatment model, with AMH, AFC and body weight as new 325 
predictors in the model. Predictions are presented for couples with two years of primary infertility caused 326 
by a male factor, and differentiation is based on female age (30 or 40 years), AMH (2.0 or 0.5 ng/mL) and 327 
AFC (15 or 7). In all scenarios the female body weight is 70 kilograms. A 30-year-old woman with an 328 
average ovarian reserve at the start of her first treatment – indicated by an AMH of 2.0 ng/mL and an 329 
AFC of 15 –  has a predicted probability of a live birth of 0.37 in the first cycle and 0.69 over three cycles 330 
(0.17 and 0.37 for a 40-year-old woman). If this woman has a reduced ovarian reserve – indicated by an 331 
AMH of 0.5 ng/mL and an AFC of 7 – the predicted probabilities decrease to 0.19 and 0.42, respectively 332 
(0.08 and 0.18 for a 40-year-old woman).  333 
Figure 6 shows predictions of the post-treatment model, which revises the predicted probabilities of the 334 
pre-treatment models by adding information of the first treatment cycle. Predictions are calculated for 335 
women with two years of primary, non-tubal infertility and are differentiated by female age (30 or 40 336 
years), number of oocytes (10 or 5) and embryo cryopreservation (yes or no). In all scenarios the woman 337 
received a cleavage stage single embryo transfer. The predicted probabilities of a live birth for women 338 
with a favourable prognosis – aged 30-years, 10 oocytes retrieved and cryopreserved embryos – is 0.49 in 339 
the first ICSI cycle, increasing to 0.83 over 3 complete cycles. In contrast, for women with a poorer 340 
prognosis – aged 40 years, 5 oocytes retrieved and no embryos cryopreserved – the predicted probabilities 341 
are 0.11 and 0.26, respectively.  342 
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Discussion 343 
Main findings 344 
This external validation study of the McLernon pre-treatment and post-treatment model found that, after 345 
minor recalibration of the intercept of the pre-treatment model, both models accurately predict the 346 
cumulative probability of live birth up to three complete IVF/ICSI cycles in a more contemporary cohort 347 
in another country. The discriminatory capacity of the pre-treatment model in an external cohort was 348 
limited, whereas the post-treatment model had a fair ability to discriminate between couples with and 349 
without a live birth after treatment. 350 
Strengths 351 
This study focuses on the external validation of an IVF prediction model, which is an essential but 352 
frequently overlooked step before implementation of a prediction model in clinical practice (Altman et 353 
al., 2009). In contrast to redeveloping new models for the same outcome, external validation and updating 354 
of existing models prevents the loss of scientific information by combining the information captured in 355 
the original model with information of a new patient cohort (Moons, Kengne, Grobbee, et al., 2012).  356 
Embryo cryopreservation has become an important part of IVF/ICSI treatment, and most couples have 357 
more than just one complete treatment cycle (Wong et al., 2014). Unlike previous prediction models 358 
(Leushuis et al., 2009; van Loendersloot et al., 2014), the McLernon models provide a more useful 359 
estimate of cumulative treatment success. As such, the validation of these models represents a significant 360 
step forward in creating a clinically useful tool to manage expectations and to inform decision making 361 
around IVF. 362 
This study benefits from the prospective design of the OPTIMIST study, which has ensured reliable data 363 
collection, with relatively low numbers of missing values and a low risk of selection bias. The multicentre 364 
design resulted in a highly representable cohort for Dutch fertility care. And although it is known that the 365 
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IVF/ICSI success rates vary between fertility centres, the inclusion of multiple centres will increase the 366 
generalisability and applicability of the external validation of the McLernon models within the 367 
Netherlands.  368 
Furthermore, the external validation was performed on data collected in a recent time period (2011-2014). 369 
Due to changing patient populations, new treatment protocols, improving technologies and increasing 370 
success rates over time, prediction models in reproduction medicine have no static form and should be 371 
regularly updated to optimally reflect the latest circumstances in which they are used (Altman et al., 372 
2009). As the McLernon models were developed on data collected between 1999 and 2009, data of the 373 
more recently performed OPTIMIST study were helpful to investigate if model performance was still 374 
accurate in current practice.  375 
Weaknesses 376 
This study has a number of limitations. First, the external validation involved data from a prospective 377 
cohort study within which two randomised controlled trials were embedded evaluating the effectiveness 378 
of individualised doses of gonadotropins based on AFC. Strict dosing regimens might have affected some 379 
treatment outcomes, such as cancellation rates and number of oocytes, thus influencing the predictive 380 
capacity of the models in the validation sample. However, as the OPTIMIST study found no difference 381 
between the dosing regimens on cumulative live birth rates, the impact on model performance is likely to 382 
be minimal.  383 
Second, the OPTIMIST study used strict eligibility criteria. Therefore, the validation sample does not 384 
fully represent the diversity of the patient population initiating IVF/ICSI treatment in the Netherlands. As 385 
none of the women in the validation sample were anovulatory, external validation of the models was only 386 
performed for an ovulatory population. This limits the generalisability of the models to some extent, as 387 
the original McLernon models were developed in a population which also included anovulatory women. 388 
Also, it could have had some impact on model performance. However, since anovulation had only a small 389 
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predictive value in the pre-treatment model, and the majority of couples underwent IVF/ICSI for other 390 
indications, a large impact on model performance is unlikely.  391 
Third, the OPTIMIST study had a follow up period of 18 months, leading to small numbers of women 392 
with more than three complete treatment cycles. Model performance could therefore only be reliably 393 
validated up to three complete cycles. However, most couples in the Netherlands complete a maximum of 394 
three treatment cycles which is partly due to the national reimbursement policy, but also by the high rates 395 
of embryo cryopreservation, increasing the number of embryo transfers and LBR per cycle. Therefore, 396 
model validation up to three complete cycles has particular clinical relevance for current Dutch fertility 397 
care.  398 
Last, the original McLernon prediction models were developed on linked cycle data, which were then 399 
used to estimate cumulative pregnancy chances. Therefore, these models used the optimistic assumption 400 
that the cumulative LBR in couples who discontinue IVF treatment without a live birth would have been 401 
equal to that of couples who continue further treatment cycles, after correction of predictor effects. This 402 
assumption tends to lead to overestimation of the cumulative LBR, as women with a low prognosis of 403 
achieving a live birth are generally more likely to discontinue treatment (Brandes et al., 2009; Olivius et 404 
al., 2004). Since the reasons for treatment withdrawal were unknown in the current external validation 405 
study, a similar method was used that probably resulted in some degree of overestimation of the 406 
cumulative LBR in the validation cohort. However, as the original McLernon models were developed 407 
with this approach, and the predictions for cumulative LBR over multiple complete cycles were 408 
considered to be clinically more relevant than per cycle predictions, we feel that the current method is the 409 
best option for the external validation of the McLernon models. 410 
Explanation of findings  411 
The discriminatory capacity of the pre-treatment model was markedly lower in the validation sample than 412 
in the development sample. In the development study, a c-statistic of 0.73 (95% CI 0.72-0.74) was 413 
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reported, whereas the present study found a c-statistic of 0.62 (95% CI 0.59-0.64). For the post-treatment 414 
model, the discriminatory performance in the validation sample was comparable to that in the 415 
development sample, with a c-statistic of 0.71 (95% CI 0.69-0.74) and 0.72 (95% CI 0.71-0.73) 416 
respectively (McLernon et al., 2016). As it is known that prediction models tend to perform too 417 
optimistically in the development dataset due to overfitting, some reduction in model performance is to be 418 
expected during external validation due to the differences between samples (Altman et al., 2009; Moons, 419 
Kengne, Woodward, et al., 2012). This, to some extent, also explains the lower overall performance of 420 
the pre-treatment model. The comparable performance of the post-treatment model in both samples 421 
indicates that the treatment related variables that were added to this model (number of oocytes, 422 
cryopreservation of embryos, and the number and stage of embryos) are important predictors for live birth 423 
after treatment. 424 
Other than the influence of overfitting, some key differences between the Dutch and UK healthcare 425 
systems may also have affected the models’ performance in this external validation study. An important 426 
factor is the reimbursement policy for fertility treatment. All Dutch infertile couples are insured for a 427 
minimum of three complete IVF/ICSI cycles. In contrast, most couples in the UK receive no standard 428 
funding for ART (Berg Brigham et al., 2013). Since IVF/ICSI treatment is expensive, this induces 429 
discrepancies in the patient population initiating and continuing treatment between the two study samples 430 
(Rajkhowa et al., 2006). As can be seen in the baseline table (Table I) and flowchart (Figure 1), couples 431 
in the UK had a longer average duration of infertility before starting treatment and were more likely to 432 
discontinue treatment after the first and second cycles than couples in the Netherlands. Also, the decrease 433 
in LBR is more evident in the UK than in the Netherlands over the first three cycles, which suggests that 434 
differences exist in both reasons for discontinuation as well as prognostic profiles of women 435 
discontinuing treatment in the two countries. These phenomena are, in part, financially driven, and could 436 
partially explain the difference in predictive ability of the UK models in the Dutch cohort.   437 
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Furthermore, despite the fact that the infertility guidelines of both countries include similar approaches 438 
for treatment of infertile couples, there are important variations in treatment characteristics between the 439 
two study samples (Dutch Society of Obstetrics and Gynaecology (NVOG), 2010; National Institute for 440 
Health and Care Excellence (NICE), 2013). Some of these differences are mainly due to changes in 441 
clinical practice over time. As is shown by the baseline table (Table 1), women in the more recent Dutch 442 
cohort (2011-2014) generally had a single embryo transfer in their first fresh treatment cycle, whereas 443 
women in the earlier UK cohort (1999-2009) most often had a double embryo transfer. Also, embryo 444 
cryopreservation was performed in over half of the Dutch women as compared to only a quarter of the 445 
women in the UK. Other differences are explained by variation in treatment protocols between 446 
geographic locations. For one, no blastocyst stage embryos transfers were performed in the Netherlands in 447 
contrast to the proportion of blastocyst stage embryo transfers in the UK of more than 10%. Also, Dutch 448 
women more frequently had no embryo available for transfer after their first treatment cycle, which is 449 
most likely caused by strict cancellation criteria particularly for hyper response. These differences in 450 
treatment characteristics suggest that the development sample does not fully reflect clinical practice in a 451 
more recent time period and in a different geographic context. As cumulative LBR are substantially 452 
affected by the variation in treatment characteristics (Glujovsky et al., 2016; Pandian et al., 2013; Wong 453 
et al., 2014), this could explain part of the different performance of the pre-treatment model in the 454 
validation sample . The stable performance of the post-treatment model, which includes embryo stage and 455 
embryo cryopreservation as important predictors, seems to confirm the impact of the variation in these 456 
variables on model performance.  457 
The addition of measures of ovarian reserve, i.e. AMH and AFC, and body weight to the McLernon 458 
prediction models revealed only a marginal improvement of model performance in the OPTIMIST 459 
dataset. The additional value of these tests can therefore be questioned, especially in view of the extra 460 
costs and physical burden on the patient. Female age is one of the most important predictors in the 461 
McLernon models (McLernon et al., 2016). As female age is correlated with the ovarian reserve, adding 462 
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AMH and AFC provides limited new information to the prediction models. This is in line with previous 463 
studies that showed that ovarian reserve tests have no added value to the use of female age alone in the 464 
prediction of ongoing pregnancy after treatment (Broer et al., 2013). Other potential predictors for live 465 
birth, such as ethnicity, smoking status and alcohol intake, were not included in this update of the 466 
McLernon model (Dhillon et al., 2015; Rossi et al., 2011; Waylen et al., 2009). The additional value of 467 
these variables for model performance was considered uncertain, as the reporting is remarkably subjective 468 
and/or often incomplete (Liber and Warner, 2018; Stockwell et al., 2016). 469 
Clinical implications 470 
Discrimination and calibration have been recognized as measures to evaluate the performance of 471 
prediction models (Altman et al., 2009; Steyerberg, 2009). However, the discriminative ability at the 472 
binary level of most prediction models in reproductive medicine, as expressed by the c-statistic, is 473 
considerably low (Leushuis et al., 2009). As at the moment of prediction the outcome of pregnancy has 474 
not yet occurred, the c-statistic is determined using the calculated probability of pregnancy. The 475 
maximum value of the c-statistic depends on the variability of these calculated probabilities in the 476 
infertile population. Since infertility is a complex and multifactorial health problem and due to the 477 
absence of strong predictors for live birth – particularly pre-treatment – , the probability distribution in 478 
infertile couples that have a live birth has a considerable overlap with the distribution of those without a 479 
live birth. Therefore the maximum c-statistic can be expected to be low (Cook, 2007; Coppus et al., 480 
2009), as is seen in the external validation of the pre-treatment model. However, this does not necessarily 481 
imply that such prediction models have limited use in clinical practice. Models with reliable predictions 482 
and a clinically useful distribution of probabilities for achieving a live birth, as assessed by calibration, 483 
can still support patients and clinicians in clinical decision making around infertility treatment (Coppus et 484 
al., 2009). 485 
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As the calibration plots of both the recalibrated pre-treatment model and the post-treatment model 486 
indicate accurate predictions with a useful range of prognoses, these models can be used within the 487 
Netherlands as counselling tools to complement clinical reasoning at two certain time points. Before 488 
initiating treatment, the recalibrated pre-treatment model offers couples and clinicians a personalised and 489 
objective estimate of success over multiple complete treatment cycles. And after the first fresh embryo 490 
transfer, the post-treatment model provides a revised estimate using treatment related information to 491 
personalize the predictions even more. Despite the applicability of the models as counselling tools to 492 
inform patients about their prognosis, the McLernon models should not yet be used for decisions on 493 
whether or not to withhold fertility treatment. The impact of such model-based decisions on cost-benefit 494 
outcomes should be investigated first and proven to be beneficial. To implement the McLernon models as 495 
counselling tools in other countries as well, national recalibration is recommended to account for 496 
geographical differences in IVF/ICSI treatment. 497 
The McLernon models were converted into an online calculator to facilitate the use of the models in 498 
clinical practice (https://w3.abdn.ac.uk/clsm/opis). As the original pre-treatment model overestimates 499 
cumulative LBR for couples in the Netherlands, conversion of the recalibrated pre-treatment model into a 500 
new online calculator is needed for implementation in Dutch clinical practice. This tailored online 501 
calculator can then provide accurate and up to date predictions for couples and clinicians in the 502 
Netherlands. Ultimately, the online calculator will be offered for implementation on the websites of the 503 
Dutch Patient Association for people with fertility problems ‘Freya’ and the Dutch Association of 504 
Obstetrics and Gynaecology (NVOG) to increase the accessibility of the models.  505 
Research implications 506 
Following this external validation study, future studies could focus on the impact of introducing the 507 
McLernon prediction models in clinical practice, and assess changes in patient and clinicians’ behaviour 508 
and its effects on LBR and cost-effectiveness.   509 
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In conclusion, after minor recalibration of the pre-treatment model, the McLernon models have proven to 510 
be valid in predicting the chance of cumulative live birth after multiple complete treatment cycles in 511 
another geographical context and in a more recent time period. Updating the models with AMH, AFC and 512 
body weight revealed only a marginal improvement of predictive performance. Following national 513 
recalibration, implementation of the McLernon models as counselling tools in clinical practice will 514 
provide infertile couples and clinicians with objective and personalized estimates of success over multiple 515 
complete IVF/ICSI cycles. 516 
  517 
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Tables 662 
Table I Characteristics of patient and treatment variables included as predictors in the development 663 
sample (HFEA cohort) and the validation sample (OPTIMIST cohort) (McLernon et al., 2016).  664 
Characteristics HFEA cohort OPTIMIST cohort Missing 
values in 
OPTIMIST 
cohort (%) 
No of women 113 873 1 511  
No of complete cycles 184 269 2 881  
    
Patient characteristics    
Age (years), mean (SD) 34.1 (5) 33.5 (5) 2 (0.1) 
Duration of infertility (years), median (IQR) 4 (3-6) 2 (2-3) 18 (1.2) 
No previous pregnancy in couple   75 541 (66) 917 (61) 2 (0.1) 
Cause of infertility:    
- Tubal factor 26 545 (23) 158 (11)  
- Male factor 49 753 (44) 839 (56)  
- Anovulatory  15 942 (14) NA by protocol  
- Endometriosis 7 590 (7) 60 (4)  
- Unexplained  32 693 (29) 521 (35) 
 
 
Body weight (kg), mean (SD) NA 69.5 (13) 36 (2.4) 
Anti-Müllerian hormone (ng/mL), median (IQR) NA 1.9 (1-3) 169 (11.2) 
Antral follicle count (2-10mm), median (IQR) NA 13 (9-18)  
    
Treatment characteristics of first completed 
cycle 
   
IVF 67 511 (59) 830 (55)  
ICSI 46 362 (41) 681 (45)  
No of oocytes retrieved, median (IQR) 8 (5-13) 8 (5-13)a 1 (0.1) 
No of embryos created, median (IQR) 5 (2-8) 4 (2-7)a 4 (0.3) 
No of embryos frozen, median (IQR) 0 (0-1) 1 (0-3)a 6 (0.5) 
Cryopreservation of embryos  28 950 (25) 726 (48)  
Fresh embryo transfer: stage and no. of 
transferred embryos: 
  24 (1.6) 
- Cleavage stage SET 9 248 (8) 1 004 (66)  
- Cleavage stage DET 75 701 (66) 125 (8)  
- Cleavage stage TET 8 649 (8) 4 (0.3)  
- Blastocyst stage SET 662 (1) NA  
- Blastocyst stage DET 2 960 (3) NA  
- Blastocyst stage TET 130 (0.1) NA  
- No transfer 15 501 (14) 354 (23)  
    
Data are presented as number (%) unless  otherwise specified. IQR; interquartile range, NA; not available, SET; 665 
single embryo transfer, DET; double embryo transfer, TET; triple embryo transfer. 666 
 a) Median is calculated over 1293 women who had an ovarian follicle aspiration. 667 
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Figures 668 
Figure 1: Flow chart presenting the numbers (%) of live birth, treatment continuation and discontinuation 669 
over six complete cycles in the OPTIMIST and HFEA databases (McLernon et al., 2016).   670 
 671 
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 672 
Figure 2: Calibration plots showing the association between the calculated and observed cumulative live 673 
birth rates over 3 complete IVF/ICSI cycles in the OPTIMIST cohort for a) the original pre-treatment 674 
model as described by McLernon et al (McLernon et al., 2016) b) recalibrated pre-treatment model with 675 
adjustment of the intercept.   676 
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Figure 3: Calibration plot showing the association between the calculated and observed cumulative live 680 
birth rates over 3 complete IVF/ICSI cycles in the OPTIMIST cohort for the original post-treatment 681 
model as described by McLernon (McLernon et al., 2016). 682 
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Figure 4:  Example of the recalibrated pre-treatment model predicting the cumulative probability of a 685 
live birth up to three complete ICSI cycles for a woman with primary infertility caused by a male factor, 686 
aged 30 or 40 years with an infertility duration of two or five years. 687 
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Figure 5: Example of the with AMH, AFC and body weight updated pre-treatment model predicting the 690 
cumulative probability of a live birth up to three complete ICSI cycles for a woman with two years of 691 
primary infertility caused by a male factor, aged 30 or 40 years, a total body weight of 70 kilograms, with 692 
an AMH of 2.0 or 0.5 ng/mL and an AFC of 15 or 7.  693 
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 695 
Figure 6: Example of the post-treatment model predicting the cumulative probability of a live birth up to 696 
three complete ICSI cycles for a woman with two years of primary infertility caused by a male factor, 697 
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aged 30 or 40 years, with 5 or 10 oocytes retrieved, a cleavage stage single embryo transfer, with or 698 
without embryo cryopreservation. 699 
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Supplementary Figure 1. Plots showing the adjusted relation between the predictors included in the 702 
updated McLernon pre-treatment model and the probability of a live birth after IVF/ICSI treatment.  703 
Predictor; linear predictor (XB) of the original pre-treatment model as described by McLernon 704 
(McLernon et al. 2016), Weight; female body weight in kg, AFC; antral follicle count (2-10mm), AMH; 705 
anti-Müllerian hormone (ng/mL) 706 
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Supplementary Figure 2. Plots showing the adjusted relation between the predictors in the updated 709 
McLernon post-treatment model and the probability of a live birth after IVF/ICSI treatment.  710 
Predictor: linear predictor (XB) of the original post-treatment model as described by McLernon 711 
(McLernon et al 2016); AFC; antral follicle count (2-10mm), AMH; anti-Müllerian hormone (ng/mL) 712 
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